clinical trial · NCT06121180
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 32
Metastatic Uveal MelanomaZIV-AfliberceptCemiplimab
brief summary
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.
started
Nov 4, 2024
primary completion
Oct 31, 2030
completion
Oct 31, 2030
last updated
Dec 4, 2025
official title
A Phase II Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol